Publication | Closed Access

Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: Final results from CALGB trial 79809

Calgb Trial 79809Bone DiseaseZoledronic AcidBone HealthMedicineClinical NutritionAdjuvant ChemotherapyGynecologyMenopauseOsteoporosisBone DensityOncologyOrthopaedic SurgeryBone MetabolismGynecology OncologyWomen's HealthOvarian CancerHealth Sciences